Racial Differences in the Use of Adjuvant Chemotherapy for Breast Cancer in a Large Urban Integrated Health System

Table 3

Logistic regression analysis of predictors of the receipt of adjuvant chemotherapy.

	Unadjusted OR (95% C.I.)	Clinical factors OR* (95% C.I.)	Societal factors OR* (95% C.I.)	Adjusted OR* (95% C.I.)
African American	1.22 (1.02–1.46)	0.88 (0.67–1.14)	1.60 (1.26–2.04)	1.01 (0.72–1.42)
Age at diagnosis^a	0.92 (0.91–0.93)	0.91 (0.90–0.92)		0.92 (0.91–0.94)
Large tumor^b	4.66 (3.85–5.63)	3.71 (2.81–4.89)		3.76 (2.84–4.98)
Lymph node positive	8.99 (7.24–11.16)	10.18 (7.54–13.74)		10.28 (7.58–13.94)
ER−/PR−	3.68 (2.97–4.56)	3.49 (2.57–4.74)		3.56 (2.61–4.85)
Moderate/High grade	3.37 (2.63–4.32)	1.40 (1.00–1.98)		1.44 (1.02–2.04)
CCI^c	0.68 (0.61–0.76)	0.93 (0.79–1.10)		0.95 (0.81–1.13)
Deprivation index^d	0.95 (0.89–1.01)		0.91 (0.84–0.99)	0.95 (0.85–1.07)
Medicare^e	0.18 (0.15–0.22)		0.18 (0.15–0.22)	0.48 (0.34–0.68)
Other insurance^e	0.66 (0.43–1.03)		0.68 (0.44–1.07)	0.43 (0.22–0.85)

^∗Models adjusted for all listed variables.
^aContinuous variable.
^b≤2 cm is the referent.
^cCharlson comorbidity index; continuous variable capped at 3.
^dQuintiles, the least deprived area (quintile 1) is the referent.
^ePrivate insurance is the referent.